Since last few decades, search for Alzheimer’s cure has been the focus of several researchers. Recently, an experimental Alzheimer’s drug, developed by Biogen Idec, Inc., has furnished promising results in an early-stage study, rekindling the hope after a series of failures. The drug targets plaque formation which actually slows the cognitive function in people diagnosed with early to mild forms of Alzheimer’s. However, the company has mentioned that the treatment still requires undergoing longer and larger trials across different categories.
Christopher Raymond, a Robert W. Baird analyst said “While still very early, these data are more impressive than anything we’ve seen in [Alzheimer’s disease], justifying the pre-data excitement”. The drug, called BIIB037, helps to clean the beta amyloid formation in the brain. Many other drugs tested previously for a similar action failed in their late-stage trials. To measure the efficacy of the drug, 54 patients were subjected to two cognitive tests over a span of two weeks. The trial aimed to determine the safety of the drug and the results that were released on Friday were found to be “acceptable.”
No fluid buildup was noted outside their blood vessels, which is one of the serious complications. However, only 22% of the patients had headaches. Geoffrey Porges, a Bernstein analyst explained “The reduction in the level of cognitive decline was higher than we had expected…In short, the more drug [that] patients took, the less their cognition declined, and the longer they took it, the bigger the difference between treated and control patients.” The study received good feedbacks and Biogen’s stocks also surged higher. Biogen Idec, Inc. is especially known for its multi-sclerosis therapies which gathered at least 9.7 billion in sales last year.